BRIEF published on 09/18/2024 at 07:05, 1 year 5 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 5 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 7 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
PRESS RELEASE published on 08/05/2024 at 07:00, 1 year 7 months ago Relief Therapeutics Secures up to $11 Million from Royalty Sales Relief Therapeutics secures $11 million from royalty sales for RLF-TD011 clinical development and pipeline advancement. Funding from SWK Holdings Corporation to support rare disease treatment options SWK Holdings Corporation Clinical Development Relief Therapeutics Rare Diseases Royalty Sales
BRIEF published on 06/27/2024 at 12:50, 1 year 8 months ago Relief Therapeutics Holding SA Reports Results of Annual General Meeting Board Of Directors Shareholders Financial Statements Relief Therapeutics AGM Results
PRESS RELEASE published on 06/27/2024 at 12:45, 1 year 8 months ago RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting RELIEF THERAPEUTICS Holding SA announces the results of its Annual General Meeting of Shareholders in Geneva. Details on approved resolutions and election outcomes Annual General Meeting Shareholders Resolutions RELIEF THERAPEUTICS Holding SA Geneva
Published on 03/16/2026 at 22:30, 5 hours 31 minutes ago Core Silver Intersects High-Grade Copper-Molybdenum Veins up to 7.31% Cu & 1.01% Mo Confirming Large Porphyry System at Laverdiere
Published on 03/16/2026 at 22:00, 6 hours 1 minute ago Viemed Healthcare to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Published on 03/16/2026 at 21:30, 6 hours 31 minutes ago Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity
Published on 03/16/2026 at 21:00, 7 hours 1 minute ago Amdocs Brings AI-Accelerated Application Modernization to Enterprises with NVIDIA
Published on 03/17/2026 at 03:40, 21 minutes ago SANY and OCHA Sign Partnership Agreement at HNPW 2026
Published on 03/17/2026 at 02:10, 1 hour 51 minutes ago Clawchain.ai Launches on Chromia to Support the Next Generation of AI Agent Systems
Published on 03/17/2026 at 00:00, 4 hours 1 minute ago Cango Inc. Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results
Published on 03/16/2026 at 23:07, 4 hours 54 minutes ago KION brings physical AI into live warehouse operations at GTC 2026 in San José, California
Published on 03/16/2026 at 22:35, 5 hours 26 minutes ago Nscale and Microsoft Announce Collaboration with NVIDIA and Caterpillar to Deliver 1.35GW of NVIDIA Vera Rubin NVL72 GPUs at Flagship AI Factory Campus in West Virginia
Published on 03/16/2026 at 18:00, 10 hours 1 minute ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:58, 10 hours 3 minutes ago Aéroports de Paris S.A - February 2026 traffic figures
Published on 03/16/2026 at 17:56, 10 hours 5 minutes ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
Published on 03/16/2026 at 17:35, 10 hours 26 minutes ago Disclosure of transactions in own shares from March 9 to March 13, 2026
